Janssen Israel and Sheba ARC

Janssen Israel and Sheba ARC, we want to be.an innovation hub set up by Sheba Medical Center to develop and promote digital health Solutions

“ Our strategy, as is Sheba's is to lead by innovation. We're a very patient-centric company with the goal to 'go beyond the pill' - adding value to our customers and maximizing treatment results.”

As the pharmaceutical division of Johnson & Johnson, Janssen focuses on developing innovative molecules for patients in different therapeutic areas, to serve unmet medical needs. This aligns well with Sheba's position as one of the world's most digitally advanced hospitals.

The Sheba ARC Center (Accelerate, Redesign, Collaborate) brings together key players in digital medicine - physicians, researchers, start-ups, investors, and top-tier medical centers with the goal of redesigning healthcare.

“Our innovation room at ARC physically connects us to the main players there and encourages us all to collaborate”, said Clive Kaye, Managing Director for Janssen Israel.

"Our strategy - as is Sheba's - is to lead by innovation. We're a very patient-centric company with the goal to 'go beyond the pill' - adding value to our customers and maximizing treatment results”.

Janssen is partnering with Sheba in three key areas:

1. Supporting promising Israeli digital medicare solutions

2. Getting valuable insights into the patient's journey, using synthetic data

3. Being on-site at ARC to interact with the main ecosystem players

“Our partnership with Sheba consists in finding technological solutions, looking at the therapeutic areas where we wish to focus, plus working with researchers and technology partners-usually start-ups”, said Clive.

He adds: “We currently focus on some digital health projects including areas such as Psychiatry, Gastroenterology and Oncology”.

Janssen Conducts research using synthetic data provided by MDClone. Performing research while using such data makes it easier and simpler to locate any event along a patient's journey without having to worry about patients' privacy issues.

Professor Eyal Zimlichman, the Chief Medical Officer as well as the Chief Innovation Officer at Sheba, added: “Janssen was the first industry partner who we signed. We learned very quickly that they share our audacity about where we want to be."

READ THE FULL SHEBA ARC DIGITAL REPORT HERE

Share

Featured Articles

Musk’s multibillion hostile Twitter takeover – the timeline

As billionaire entrepreneur Elon Musk buys Twitter for US$44bn, we draw up a timeline, from the buying of shares to the critical tweets and unsolicited bid

Sustainable moves businesses can make to win customers, IBM

With half of consumers saying environmental sustainability is more important today than a year ago, businesses should up their eco action, says IBM report

Banks and consultancies top workplaces to grow career in UK

Financial and professional services firms rank highest in LinkedIn Top 25 best workplaces list – from Barclays, Lloyds and HSBC, to PwC, Deloitte and EY

Top 10 women in technology in Europe

Leadership & Strategy

The value of ESG links sustainability to business returns

Sustainability

Top 10 European football clubs by revenue 2022 – Deloitte

Corporate Finance